{
  "041.SG": {
    "city": "CÃ¡diz",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "ADL Bionatur Solutions, S.A.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ADL Bionatur Solutions S.A. Acc",
    "state": null,
    "summary": "ADL Bionatur Solutions, S.A. engages in the research, development, manufacturing, and commercialization of products in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is headquartered in CÃ¡diz, Spain.",
    "website": "http://www.adlbionatur.com",
    "zipcode": "11591"
  },
  "41L.F": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Laboratorios Farmaceuticos Rovi, S.A.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "LABORATORIOS FARMACEUT.",
    "state": null,
    "summary": "Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and MedicebrÃ¡n to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT ExprÃ¨s that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios FarmaceÃºticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.",
    "website": "http://www.rovi.es",
    "zipcode": "28223"
  },
  "ADL.MC": {
    "city": "CÃ¡diz",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "ADL Bionatur Solutions, S.A.",
    "market": "es_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ADL BIONATUR SOLUTIONS, S.A.",
    "state": null,
    "summary": "ADL Bionatur Solutions, S.A. engages in the research, development, manufacturing, and commercialization of products in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is headquartered in CÃ¡diz, Spain.",
    "website": "http://www.adlbionatur.com",
    "zipcode": "11591"
  },
  "ATRY.MC": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Atrys Health, S.A.",
    "market": "es_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ATRYS HEALTH, S.A.",
    "state": null,
    "summary": "Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools. Atrys Health, S.A. was founded in 2007 and is based in Barcelona, Spain.",
    "website": "http://www.atryshealth.com",
    "zipcode": "08025"
  },
  "BIO.MC": {
    "city": "Granada",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Biosearch, S.A.",
    "market": "es_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOSEARCH, S.A.",
    "state": null,
    "summary": "Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.",
    "website": "http://www.biosearchlife.es",
    "zipcode": "18004"
  },
  "LABFF": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Laboratorios Farmaceuticos Rovi, S.A.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "LABORATORIOS FARMACEUTOCOS ROVI",
    "state": null,
    "summary": "Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and MedicebrÃ¡n to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT ExprÃ¨s that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios FarmaceÃºticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.",
    "website": "http://www.rovi.es",
    "zipcode": "28223"
  },
  "ORN.F": {
    "city": "CornellÃ  de Llobregat",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Oryzon Genomics S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ORYZON GENOMICS SA EO-,05",
    "state": null,
    "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in CornellÃ  de Llobregat, Spain.",
    "website": "http://www.oryzon.com",
    "zipcode": "08940"
  },
  "ORY.MC": {
    "city": "CornellÃ  de Llobregat",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Oryzon Genomics S.A.",
    "market": "es_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ORYZON GENOMICS, S.A.",
    "state": null,
    "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in CornellÃ  de Llobregat, Spain.",
    "website": "http://www.oryzon.com",
    "zipcode": "08940"
  },
  "ORYZF": {
    "city": "CornellÃ  de Llobregat",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Oryzon Genomics S.A.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ORYZON GENOMICS SA",
    "state": null,
    "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in CornellÃ  de Llobregat, Spain.",
    "website": "http://www.oryzon.com",
    "zipcode": "08940"
  },
  "PHM.MC": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Pharma Mar, S.A.",
    "market": "es_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMA MAR, S.A.",
    "state": null,
    "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.",
    "website": "http://www.pharmamar.com",
    "zipcode": "28770"
  },
  "PHMMF": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Pharma Mar, S.A.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMA MAR SA",
    "state": null,
    "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.",
    "website": "http://www.pharmamar.com",
    "zipcode": "28770"
  },
  "PMRA.F": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pharma Mar, S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMA MAR S.A. EO -,60",
    "state": null,
    "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.",
    "website": "http://www.pharmamar.com",
    "zipcode": "28770"
  },
  "PUL.F": {
    "city": "Granada",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biosearch, S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOSEARCH S.A.INH. EO-,24",
    "state": null,
    "summary": "Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.",
    "website": "http://www.biosearchlife.es",
    "zipcode": "18004"
  },
  "ROVI.MC": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Laboratorios Farmaceuticos Rovi, S.A.",
    "market": "es_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "LABORATORIOS FARMACEUTICOS ROVI",
    "state": null,
    "summary": "Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and MedicebrÃ¡n to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT ExprÃ¨s that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios FarmaceÃºticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.",
    "website": "http://www.rovi.es",
    "zipcode": "28223"
  }
}
